---
document_datetime: 2024-09-18 14:57:54
document_pages: 17
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/comtan-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: comtan-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 11.6271817
conversion_datetime: 2025-12-31 01:51:25.901737
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Comtan

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                 | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| N/0063               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                      | 05/09/2024                          |                                             | PL                               |           |
| IA/0062              | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites | 29/05/2023                          | n/a                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                    | (excluding manufacturer for batch release)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |     |                                   |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| PSUSA/1223/ 202201 | Periodic Safety Update EU Single assessment - entacapone                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 01/09/2022 | n/a | PRAC Recommendation - maintenance |
| WS/2202/G          | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.z - Quality change - Active substance - Other variation B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting | 31/03/2022 | n/a |                                   |
| IB/0060/G          | This was an application for a group of variations. B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation                                                                                                                                                                                                                                                                                                                                                        | 28/02/2022 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|           | to in-process tests or limits applied during the manufacture of the finished product - Other variation B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation                                                                                                                                                                                                                                                                                       |            |            |                                  | B.II.b.5.z - Change   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------|
| N/0058    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 11/10/2021 | 02/06/2022 | PL                               |                       |
|           | This was an application for a group of variations. B.II.e.1.b.3 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Deletion of an immediate packaging container without a complete deletion of a strength or pharmaceutical form A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.7 - Administrative change - Deletion of manufacturing sites C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation | 07/04/2021 | 02/06/2022 | SmPC, Annex II, Labelling and PL | IB/0057/G             |
| WS/1735/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 12/03/2020 | n/a        |                                  |                       |

<div style=\"page-break-after: always\"></div>

|           | B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.d.1.b.3 - Stability of AS - Change in the storage conditions - Change in storage conditions of the AS B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF                                                                                                         |            |            |                              | 1234/2008.   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------------|--------------|
| IAIN/0056 | B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes                                                                                                                                                                                                                                                                                                                                                | 12/12/2019 | 24/11/2020 | SmPC and Labelling           |              |
| IB/0054/G | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.e.1.b.1 - Change in immediate packaging of the | 15/11/2019 | 24/11/2020 | SmPC, Annex II and Labelling |              |

<div style=\"page-break-after: always\"></div>

|                    | finished product - Change in type/addition of a new container - Solid, semi-solid and non-sterile liquid pharmaceutical forms B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes                                                                                                                                                                                                         |            |            |                                  |                                   |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------|
| T/0053             | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 13/09/2019 | 07/11/2019 | SmPC, Labelling and PL           |                                   |
| PSUSA/1223/ 201901 | Periodic Safety Update EU Single assessment - entacapone                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 05/09/2019 | n/a        |                                  | PRAC Recommendation - maintenance |
| IA/0051/G          | This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place | 05/12/2018 | n/a        |                                  |                                   |
| IA/0050            | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                           | 27/06/2018 | 01/07/2019 | SmPC, Annex II, Labelling and PL |                                   |

<div style=\"page-break-after: always\"></div>

| T/0049             | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 20/03/2018   | 19/04/2018   | SmPC, Labelling and PL   |                                   |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|-----------------------------------|
| IB/0048            | B.III.2.z - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 24/03/2017   | n/a          |                          |                                   |
| PSUSA/1223/ 201601 | Periodic Safety Update EU Single assessment - entacapone                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 02/09/2016   | n/a          |                          | PRAC Recommendation - maintenance |
| WS/0665            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. To update the Product Information as follows: - to include ADR statement - to update the PI to QRD template version 9 - to include an explanation to the PL of the pictogram which is currently only displayed on the carton (all products except Comtan) - to correct the local contact information for Malta in Stalevo PL - to correct the local contact information for Latvia in all PLs except for Comtan and Entacapone Orion - to correct the local contact information for Germany in Comtess and Levodopa/Carbidopa/Entacapone Orion - for Comtan only: to add 'Magnesium stearate' to the list of excipients for the film-coating in the SmPC and PL. Tablet core and Film-coating both contain | 22/01/2015   | 11/11/2015   | SmPC, Labelling and PL   |                                   |

<div style=\"page-break-after: always\"></div>

|             | - to correct linguistic amendments in Annexes - to amend a mistake in the Annex A (only for Comtan). C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                 |            |            |                                  |                                                                                                                                                                                                                                                                                                     |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0045   | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                          | 13/11/2014 | 11/11/2015 | SmPC, Labelling and PL           |                                                                                                                                                                                                                                                                                                     |
| IAIN/0044/G | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site | 10/11/2014 | n/a        |                                  |                                                                                                                                                                                                                                                                                                     |
| N/0043      | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                    | 25/10/2013 | 20/12/2013 | PL                               |                                                                                                                                                                                                                                                                                                     |
| IAIN/0042   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                      | 25/02/2013 | n/a        |                                  |                                                                                                                                                                                                                                                                                                     |
| IB/0041     | C.I.3.z - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under A 45/46, or amendments to reflect a Core SPC - Other variation       | 17/12/2012 | 20/12/2013 | SmPC, Annex II, Labelling and PL | SmPC sections 4.4 and 4.8 as well as sections 2 and 4 of the Package Leaflet were updated in line with a request from the PhVWP/CHMP for a class label change for all products containing levodopa, dopamine agonists and/or COMT inhibitors with respect to the risk of impulse control disorders. |

<div style=\"page-break-after: always\"></div>

|             |                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |            |                                  | latest QRD template versions 8.1 and 8.2. Minor typographical errors were also corrected in some of the languages.   |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------|
| IAIN/0040/G | This was an application for a group of variations. B.II.b.2.b.1 - Change to batch release arrangements and quality control testing of the FP - Not including batch control/testing B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.e.5.b - Change in pack size of the finished | 05/07/2012 | 08/10/2012 | SmPC, Annex II, Labelling and PL |                                                                                                                      |
| IB/0039/G   | This was an application for a group of variations. B.II.e.4.a - Change in shape or dimensions of the container or closure (immediate packaging) - Non- sterile medicinal products B.II.b.3.z - Change in the manufacturing process of the finished product - Other variation                                                                                                                                                            | 05/07/2012 | n/a        |                                  |                                                                                                                      |
| IB/0038     | B.III.2.a.1 - Change of specification('s) of a former non Pharmacopoeial substance to comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - AS                                                                                                                                                                                                                                                                  | 29/06/2012 | n/a        |                                  |                                                                                                                      |
| IA/0037     | B.II.b.2.a - Change to batch release arrangements                                                                                                                                                                                                                                                                                                                                                                                       | 03/11/2011 | n/a        |                                  |                                                                                                                      |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | and quality control testing of the FP - Replacement or addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |            |                       |                                                                                                                                                                                                                                                             |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0036/G | This was an application for a group of variations. Addition of a new specification parameter to the specification with its corresponding test method B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with | 12/11/2010 | n/a        |                       |                                                                                                                                                                                                                                                             |
| II/0035/G | This was an application for a group of variations. The MAH submitted a group of variations to update the SPC sections 4.4 and 4.8 and the PL of Comtan with respect to ischemic heart disease events and myocardial infarction. The SPC section 4.4 and the PL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 22/04/2010 | 10/06/2010 | SmPC, Annex II and PL | Following a request from the CHMP for entacapone- containing medicinal products, the product information has been updated with respect to ischemic heart disease events and myocardial infarction. Colitis is currently included in section 4.8 of the SPC. |

<div style=\"page-break-after: always\"></div>

|        | were updated further to the signal on colitis. In addition, the PL has been revised following the results of a user test, and changes are proposed to the Annex I, IIB and IIIB of the Comtan Product Information following the QRD template version 7.3. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data C.I.3.a - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under A 45/46, or amendments to reflect a Core SPC - Changes with NO new additional data are submitted by the MAH   |            |            |                                  | However, the MAH has now updated section 4.4 of the SPC following assessment of cumulative post-marketing safety data. Based on the new analysis, the colitis signal has not become more frequent nor increased in severity, but in order to provide additional information on the management of prolonged diarrhoea as a potential sign of colitis an update of section 4.4 is considered appropriate. The added sentence in section 4.4 states that prolonged or persistent diarrhoea appearing during use of entacapone may be a sign of colitis, and that in the event of prolonged or persistent diarrhoea, the drug should be discontinued and appropriate medical therapy and investigations considered. In addition, changes are proposed to the Annex I, IIB and IIIB of the Comtan product information following the QRD template version 7.3, and the PL has been revised following   |
|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0030 | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 26/06/2008 | 03/09/2008 | SmPC, Annex II, Labelling and PL | Based on the review of the available information the CHMP is of the opinion that the quality, the safety and the efficacy of this medicinal product continues to be adequately and sufficiently demonstrated and therefore considers that the benefit/risk profile of Comtan continues to be favourable. There is strong evidence on the positive causal relationship between impulse control disorders and antiparkinsonian therapy. However, whether these behaviours are simply related to dopaminergic medications or whether the primary pathological features of PD play a role is not known. The development of impulse control disorder has very often been linked to dopamine agonist administration, especially adjunctive agonist therapy combined with                                                                                                                               |

<div style=\"page-break-after: always\"></div>

|         |                                                                                  |            |     | levodopa-carbidopa. Cumulatively, a total of three reports with pathological gambling and eight reports with libido increased or hypersexuality have been reported for entacapone. Based on this the CHMP endorsed the MAH proposal to include a a statement regarding the terms pathological gambling, libido increased and hypersexuality in sections 4.4 and 4.8 of the SPC of Comtess. A total of four reports including a reported overdose were received during the period (16 March 2006 to 16 January 2008) and one additional report of intentional overdose was received after the Data Lock Point (DLP). Of these five reports, three were identified as actual confirmed overdoses. Based on these cases the CHMP accepted the MAH suggested new wording of the Comtess SPC section 4.9 \"Overdose\" that would read as follows: \"The post- marketing data includes isolated cases of overdose in which the reported highest daily dose of entacapone has been 16,000 mg. The acute symptoms and signs in these cases of overdose included confusion, decreased activity, somnolence, hypotonia, skin discolouration and urticaria.\"   |
|---------|----------------------------------------------------------------------------------|------------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0032 | IB_10_Minor change in the manufacturing process of the active substance          | 18/08/2008 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| IB/0031 | IB_10_Minor change in the manufacturing process of the active substance          | 18/08/2008 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| IA/0034 | IA_11_a_Change in batch size of active substance or intermediate - up to 10-fold | 17/07/2008 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| IA/0033 | IA_11_a_Change in batch size of active substance or                              | 17/07/2008 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

|         | intermediate - up to 10-fold                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0029 | IA_09_Deletion of manufacturing site                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 21/01/2008 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| IA/0028 | IA_12_a_Change in spec. of active subst./agent used in manuf. of active subst. - tightening of spec. IA_13_a_Change in test proc. for active substance - minor change                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 31/07/2007 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| IA/0027 | IA_23_b_Change in source of excip./reagent to veg./synthetic material - other cases                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 27/07/2007 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| II/0026 | This variation refers to an update of sections 4.4 and 4.8 of the Summary of Product Characteristics (SPC) and sections 2 and 4 of the Package Leaflet (PL) further to the assessment of the 10th PSUR (Periodic Safety Update Report). In addition, a precautionary statement relating to sucrose intolerance has been added to section 4.4 of the SPC. The MAH also took this opportunity to align the Product Information with the latest QRD templates and to update the list of contact details for the local representatives in the PL (including Bulgaria and Romania). Update of Summary of Product Characteristics, Labelling and Package Leaflet | 24/01/2007 | 27/02/2007 | SmPC, Annex II, Labelling and PL | During the 10th PSUR, cumulative information on 35 ADRs related to liver laboratory abnormalities or abnormal hepatic function in 29 reports had been reported. Of note, hepatitis, cytolytic hepatitis, hepatic failure, hepatotoxicity have been reported once, jaundice twice, liver disorder three times and cholestatic hepatitis four times. Cholecystitis and cholestatis have both been included in one report, and cholelithiasis in 3 reports. One case of cytolytic hepatitis preceding progressive asthenia, anorexia and loss of weight was reported with positive rechallenge. Therefore, the CHMP recommended the inclusion of a warning related to this safety concern in section 4.4 of the SPC and the inclusion of the terms \"colitis\" and \"skin, hair, beard and nail discolorations\" in section 4.8 of the SPC and relevant section of the PL. Within this type II variation, the MAH has reviewed post-marketing safety data and consequently analysed cumulative case reports of increased liver function tests associated with weight decrease, anorexia or asthenia. Additionally, the MAH provided an update of scientific literature regarding weight decrease in |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |            |            |             | Parkinson's disease. Based on these data, section 4.4 of the SPC has been updated to reflect that \"For patients who experience progressive anorexia, asthenia and weight decrease within a relatively short period of time, a general medical evaluation including liver function should be considered\". Furthermore, a precautionary statement related to sucrose intolerance was added.\"Colitis\" and \"skin, hair, beard and nail discolorations\" were included in section 4.8 of the SPC and section 4 of the PL. Addition of a new subsection \"Take special care with Comtan\" for section 2 of the PL to include all the relevant precautions and warnings was also made.           |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0024 | Change(s) to container                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 23/06/2005 | 01/08/2005 | SmPC        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| IA/0025 | IA_12_a_Change in spec. of active subst./agent used in manuf. of active subst. - tightening of spec.                                                                                                                                                                                                                                                                                                                                                                                                                   | 11/05/2005 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| II/0023 | The Marketing Authorisation Holder applied for changes to section 4.4 (Special warnings and special precautions for use) and section 4.8 (Undesirable effects) of the Summary of Product Characteristics to include information on neuroleptic malignant syndrome (NMS) and rhabdomyolysis following the assessment of the 8th PSUR. The Package Leaflet was revised accordingly. In addition, the MAH applied for the inclusion of typographical corrections to several language versions of the product information. | 20/01/2005 | 07/03/2005 | SmPC and PL | The MAH has closely monitored cases of NMS and rhabdomyolysis since the 5th PSUR and neuroleptic malignant syndrome (NMS) was mentioned in SPC section 4.4 warnings and precautions. NMS has been reported 9 times since market introduction of entacapone. In four out of nine of these cases entacapone and other PD drug treatment has been abruptly withdrawn 1-2 days before event onset. In the remaining cases many confounding factors could be recognized, severe underlying illnesses, complex drug treatments, and co-administration of entacapone with drugs reported to have been related to NMS even on their own, and these cases create no clear signal at the moment. |

<div style=\"page-break-after: always\"></div>

|         | Package Leaflet                                                                                                                                                                             |            |            |                                  | The wording on NMS in section 4.4 of the SPC has been revised to state that isolated cases of NMS have been reported, especially following abrupt reduction or discontinuation of entacapone and other concomitant dopaminergic medications. It was also added to section 4.8 of the SPC that isolated cases of NMS have been reported following abrupt reduction or discontinuation of entacapone and other dopaminergic medications. This change was also reflected in the Package Leaflet. Since market introduction 9 cases of rhabdomyolysis have been reported to the MAH. Rhabdomyolysis has been mild or moderate and other possible causal factors have been detected. Consequently information has been added to section 4.8 of the SPC that isolated cases of rhabdomyolysis have been reported.   |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0022  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                            | 09/07/2004 | n/a        | Labelling and PL                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| IA/0021 | IA_04_Change in name and/or address of a manuf. of the active substance (no Ph. Eur. cert. avail.)                                                                                          | 24/02/2004 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| R/0020  | Renewal of the marketing authorisation.                                                                                                                                                     | 24/07/2003 | 17/10/2003 | SmPC, Annex II, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| I/0016  | Change in or addition of manufacturing site(s) for part or all of the manufacturing process. 01_Change in or addition of manufacturing site(s) for part or all of the manufacturing process | 28/03/2003 | 14/05/2003 | Annex II and PL                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| I/0019  | 26_Changes to comply with supplements to pharmacopoeias                                                                                                                                     | 02/05/2003 | 06/05/2003 |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

| I/0018   | 25_Change in test procedures of the medicinal product                                                                                                                    | 02/05/2003   | 06/05/2003   |             |                    |
|----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------|--------------------|
| I/0017   | Change in the name of a manufacturer of the medicinal product. 01_Change in the name of a manufacturer of the medicinal product                                          | 28/03/2003   | 03/04/2003   |             |                    |
| I/0015   | Change in or addition of manufacturing site(s) for part or all of the manufacturing process. 01_Change in or addition of manufacturing site(s) for manufacturing process | 28/03/2003   | 03/04/2003   |             | part or all of the |
| II/0014  | Update of Summary of Product Characteristics and Package Leaflet                                                                                                         | 27/06/2002   | 30/09/2002   | SmPC and PL |                    |
| I/0011   | 12_Minor change of manufacturing process of the active substance                                                                                                         | 21/01/2002   | 06/03/2002   |             |                    |
| I/0013   | 15_Minor changes in manufacture of the medicinal product 19_Change in specification of excipients in the medicinal product (excluding adjuvants for vaccines)            | 21/12/2001   | 07/01/2002   |             |                    |
| I/0012   | 15_Minor changes in manufacture of the medicinal product                                                                                                                 | 21/12/2001   | 07/01/2002   |             |                    |
| II/0007  | Update of Summary of Product Characteristics                                                                                                                             | 27/06/2001   | 18/10/2001   | SmPC        |                    |

<div style=\"page-break-after: always\"></div>

|         | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                        | 14/09/2001   | 07/02/2002   | PL                     | N/0010   |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------|----------|
| I/0009  | 20a_Extension of shelf-life or retest period of the active substance                                                                                                                                    | 24/07/2001   | n/a          |                        |          |
| I/0008  | 12_Minor change of manufacturing process of the active substance                                                                                                                                        | 13/07/2001   | n/a          |                        |          |
| II/0006 | Update of or change(s) to the pharmaceutical documentation                                                                                                                                              | 02/04/2001   | 02/05/2001   |                        |          |
| II/0004 | Update of Summary of Product Characteristics and Package Leaflet                                                                                                                                        | 11/04/2000   | 27/07/2000   | SmPC, Labelling and PL |          |
| I/0005  | 12_Minor change of manufacturing process of the active substance                                                                                                                                        | 20/01/2000   | n/a          |                        |          |
| I/0003  | 12_Minor change of manufacturing process of the active substance 13_Batch size of active substance 12a_Change in specification of starting material/intermediate used in manuf. of the active substance | 17/05/1999   | 26/05/1999   |                        |          |
| II/0001 | New safety warning                                                                                                                                                                                      | 17/12/1998   | 07/05/1999   | SmPC and PL            |          |
| I/0002  | 11_Change in or addition of manufacturer(s) of active substance 13_Batch size of active substance                                                                                                       | 05/03/1999   | 19/03/1999   |                        |          |